All In Biotech

Free tool

FAERS Monitor: Gliadel

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020637 or its brand name (Gliadel, Carmustine). Reports on generic versions are filed under their own applications.

Reports

4,717

Serious

4,619

98% of reports

Hospitalization

1,484

Death reported

1,214

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use521
  • febrile neutropenia400
  • myelodysplastic syndrome301
  • disease progression292
  • mucosal inflammation256
  • thrombocytopenia252
  • pyrexia242
  • neutropenia211
  • pneumonia206
  • drug ineffective202
  • infection183
  • acute myeloid leukaemia172
  • diarrhoea162
  • sepsis162
  • product use in unapproved indication157

Reports by year received

View as table
YearReports
200492
2005112
2006105
2007118
2008134
2009103
201090
2011147
2012144
2013139
2014101
2015194
2016126
2017247
2018337
2019351
2020375
2021311
2022292
2023440
2024298
2025229
2026232

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,442 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelodysplastic syndromeSignal30194.784.827,266
acute myeloid leukaemiaSignal17249.742.98,083
mucosal inflammationSignal25644.039.110,629
febrile neutropeniaSignal40027.024.69,978
disease progressionSignal29211.09.92,661
thrombocytopeniaSignal25210.18.92,056
neutropeniaSignal2116.96.11,070
sepsisSignal1626.55.6749
infectionSignal1835.64.9699
pyrexiaSignal2423.12.8352
pneumoniaSignal2062.82.5247
product use in unapproved indicationSignal1572.82.4185
off label useSignal5212.72.4558
diarrhoea1621.11.02
drug ineffective2020.70.631

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.